Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Telehealth. Priority Review Voucher Reauthorization. Accelerated Approval. Newborn Screening.
2025 · 1st Quarter (Jan 1 - Mar 31)
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)
Filed by NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD).
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 16, 2025
- Income
- Not reported
- Expenses
- $50,000.00
- Filing UUID
- 0eda37d8-70df-4eee-8875-6e1f22f28074
- Termination date
- Not reported
Expense method: B
Literal source text
Lobbying issues and bill citations
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Accelerated Approval. S.705: Innovation in Pediatric Drugs Act of 2025. H.R.1414: Camerons Law. Promising Pathways Act 2.0.
Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.